RT Journal Article
SR Electronic
T1 Macula structural and vascular differences in glaucoma eyes with and without high axial myopia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.02.21263045
DO 10.1101/2021.09.02.21263045
A1 Rezapour, Jasmin
A1 Bowd, Christopher
A1 Dohleman, Jade
A1 Belghith, Akram
A1 Proudfoot, James A.
A1 Christopher, Mark
A1 Hyman, Leslie
A1 Jonas, Jost B.
A1 Penteado, Rafaella C.
A1 Moghimi, Sasan
A1 Hou, Huiyuan
A1 Fazio, Massimo A.
A1 Weinreb, Robert N.
A1 Zangwill, Linda M.
YR 2021
UL http://medrxiv.org/content/early/2021/09/10/2021.09.02.21263045.abstract
AB Aims To assess the thickness of various retinal layers, and the superficial vessel density (sVD) in the macula of glaucomatous eyes and their associations with axial length (AL) and visual field mean deviation (VFMD) to identify parameters useful for glaucoma management in myopic eyes.Methods 248 glaucoma patients (401 eyes) participating in the Diagnostic Innovations in Glaucoma Study observational cohort representing 3 axial myopia groups (non-myopia: n=146 eyes; mild myopia: n=208 eyes; high myopia (AL>26 mm): n=47 eyes) who completed macular OCT and OCT-Angiography imaging were included. The cross-sectional associations of AL and VFMD with the thickness of the ganglion cell inner plexiform layer (GCIPL), macular retinal nerve fiber layer (mRNFL), ganglion cell complex (GCC), sVD and macular choroidal thickness (mCT) were evaluated.Results Thinner Global GCIPL and GCC were significantly associated with worse VFMD (R2=35.1%; and R2=33.4%; respectively p<0.001), but not with AL (all p>0.350). Thicker mRNFL showed a weak association with increasing AL (R2=3.4%; p=0.001) and a positive association with VFMD (global R2=20.5%; p<0.001). Lower sVD was weakly associated with increasing AL (R2=2.3%; p=0.016) and more strongly associated with more severe glaucoma VFMD (R2=31.8%; p<0.001). Thinner mCT was associated with increasing AL (R2=17.3% p<0.001) and not associated with VFMD (P=0.262). mRNFL was thickest while mCT was thinnest in all sectors of high myopic eyes.Conclusions GCIPL and GCC thinned with increasing severity of glaucoma but were not significantly associated with axial length. GCIPL and GCC thickness may be useful clinical parameters to identify glaucoma in myopic eyes.Competing Interest StatementNone: JR, CB, JD, AB, JAP, MC, LH, JBJ, RCP, SM, HH, MAF RNW: Consulting: Bausch & Lomb, Eyenovia, Aerie Pharmaceuticals, Allergan; Research Funding or Equipment: Bausch & Lomb, Heidelberg Engineering, Carl Zeiss Meditec, Konan Medical, Genentech, Optos, Optovue, Centervue; Patent: Toromedes, Carl Zeiss Meditec-Zeiss LMZ: Research Funding and Equipment: Heidelberg Engineering; Research Equipment: Optovue Inc, Carl Zeiss Meditec Inc, Topcon Medical Systems Inc; Patent: Carl Zeiss Meditec. Clinical TrialNCT00221897Funding StatementGrant support: JR: German Research Foundation research fellowship grant recipient (RE 4155/1-1) and German Ophthalmological Society Grant MC: K99EY030942 SM: Tobacco-Related Disease Research Program T31IP1511 RNW: National Eye Institute R01EY029058, an Unrestricted grant from Research to Prevent Blindness (New York, NY) LMZ: National Eye Institute R01EY011008, R01EY019869, R01EY027510, P30EY022589 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board of the University of California San Diego and according to the tenets of the Declaration of Helsinki written informed consent was obtained from all patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe DIGS dataset is available upon request after appropriate data use agreements are initiated.